Efficacy, safety, and tolerability of nivasorexant in adults with binge‐eating disorder: A randomized, Phase II proof of concept trial
International Journal of Eating Disorders · 2023
DOI: 10.1002/eat.24039 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Eating Disorders, 2023. Verfasst von Susan L McElroy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lindner Center of HOPE, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Binge-Eating Disorder, Bulimia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Idorsia Pharmaceuticals Ltd.
Abstract (Originalsprache)
Objective
This Phase II, placebo‐controlled, double‐blind study investigated the efficacy, safety, and tolerability of nivasorexant in the treatment of adults with moderate to severe binge‐eating disorder (BED).
Methods
Adults meeting the DSM‐5 BED criteria were randomized 1:1 to placebo or nivasorexant (100 mg b.i.d.). The primary endpoint was the change from baseline to Week 12 in the number of binge eating (BE) days per week. Exploratory efficacy endpoints included cessation of BE in the last 4 weeks of treatment; and change from baseline to Week 12 in the number of BE episodes/week, the clinician global impression (CGI) of change, the Yale‐Brown Obsessive‐Compulsive Scale modified for BE, and the Hamilton rating scale for depression (HAMD‐17). Key safety outcomes included treatment‐emergent adverse events (TEAEs) and adverse events of special interest (i.e., somnolence and fatigue).
Results
Sixty‐eight participants were randomized to each treatment arm. The change from baseline to Week 12 in the number of BE days/week was the same for placebo (least squares mean [LSM]: −2.93) and nivasorexant (LSM: −2.93), with no difference between the treatment groups (LSM difference = .000 [95% confidence interval (CI): −.69, .69], p = .9992). Furthermore, no differences between treatment groups were observed in the exploratory efficacy endpoints. Nivasorexant was well tolerated; the overall incidence of TEAEs was balanced between treatment groups, and the frequency of somnolence and fatigue in the nivasorexant group were similar to placebo.
Discussion
In this proof‐of‐concept study, 100 mg b.i.d. nivasorexant did not improve BE in adults with moderate to severe BED. Public Significance The results of this Phase II study indicate that nivasorexant was well tolerated in adults with BED, but did not improve binge eating behavior over placebo. Further research is needed to improve our understanding of the role of the orexin‐1 receptor in BED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lindner Center of HOPE, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
- Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, USA.
- Medical Research Network, New York, New York, USA.
- Department of Psychiatry, Columbia University, New York, New York, USA.
ORCID-Profile: Susan L McElroy, Anna I Guerdjikova
Förderung
- Idorsia Pharmaceuticals Ltd
Zitieren
APA
McElroy, S. L., Coloma, P. M., Berger, B., Guerdjikova, A. I., Joyce, J. M., Liebowitz, M. R., Pain, S., & Rabasa, C. (2023). Efficacy, safety, and tolerability of nivasorexant in adults with binge‐eating disorder: A randomized, Phase II proof of concept trial. International Journal of Eating Disorders. https://doi.org/10.1002/eat.24039
Vancouver
McElroy SL, Coloma PM, Berger B, Guerdjikova AI, Joyce JM, Liebowitz MR, et al. Efficacy, safety, and tolerability of nivasorexant in adults with binge‐eating disorder: A randomized, Phase II proof of concept trial. International Journal of Eating Disorders. 2023. doi:10.1002/eat.24039
BibTeX
@article{McElroy2023,
author = {McElroy, Susan L and Coloma, Preciosa M and Berger, Benjamin and Guerdjikova, Anna I and Joyce, J Mark and Liebowitz, Michael R and Pain, Scott and Rabasa, Cristina},
title = {Efficacy, safety, and tolerability of nivasorexant in adults with binge‐eating disorder: A randomized, Phase II proof of concept trial},
journal = {International Journal of Eating Disorders},
year = {2023},
doi = {10.1002/eat.24039}
}
EUVIMED